A. Mark Dyas
Plus aucun poste en cours
Profil
A.
Mark Dyas worked as a Director of Pharmaceutical Development at Veloxis Pharmaceuticals A and as a Director & Chief Scientific Officer at IOTA NanoSolutions Ltd.
Anciens postes connus de A. Mark Dyas
| Sociétés | Poste | Fin |
|---|---|---|
IOTA NanoSolutions Ltd.
 IOTA NanoSolutions Ltd. Chemicals: Major DiversifiedProcess Industries IOTA NanoSolutions Ltd. is a nanomaterials engineering company that develops organic nanoparticles. It has actively developed a number of novel generic approaches to enable the formation of dry physical blends of insoluble and soluble materials. The blends are produced without a traditional particle formation step such as milling and are equally applicable with amorphous, crystalline or waxy materials. When the blends are added to a liquid the soluble material dissolves consequently releasing the insoluble material as a nanodispersion. The company was founded in 2005 and is headquartered in Liverpool, UK. | Directeur Technique/Scientifique/R&D | 10/10/2013 |
| VELOXIS PHARMACEUTICALS A/S | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
IOTA NanoSolutions Ltd.
IOTA NanoSolutions Ltd. Chemicals: Major DiversifiedProcess Industries IOTA NanoSolutions Ltd. is a nanomaterials engineering company that develops organic nanoparticles. It has actively developed a number of novel generic approaches to enable the formation of dry physical blends of insoluble and soluble materials. The blends are produced without a traditional particle formation step such as milling and are equally applicable with amorphous, crystalline or waxy materials. When the blends are added to a liquid the soluble material dissolves consequently releasing the insoluble material as a nanodispersion. The company was founded in 2005 and is headquartered in Liverpool, UK. | Process Industries |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
